Evidence map›Paper›PMID 42495136›Full record

ArticleFrontiers in microbiology2026

Chronic hepatitis D infection is associated with distinguishing microbial and functional features in the gut microbiome.

Meital A Gewirtz, Yue Zhang, Nivedha Vaidy, Neelam R Redekar, Nicole Minerva, James A Haddad, Jenna L Oringher, Rownock Afruza, Moumita Chakraborty, Matthew G Menkart and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Meital A GewirtzTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Yue ZhangIntegrated Data Sciences Section (IDSS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Nivedha VaidyTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Neelam R RedekarIntegrated Data Sciences Section (IDSS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Nicole MinervaTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
James A HaddadTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Jenna L OringherTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Rownock AfruzaTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Moumita ChakrabortyTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Matthew G MenkartTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Harish GopalakrishnaTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Julian HercunTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Justin LackIntegrated Data Sciences Section (IDSS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
David E KleinerLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Michail S LionakisFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Christopher KohTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.
Theo HellerTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States.

Funding

Co(II)-Radical Pair Dynamics in B12 Enzyme CatalysisR01DK054514 · NIDDK · EMORY UNIVERSITY · PI WARNCKE, KURT · 1998 to 2019
$4.2M
Investigation of management and disease manifestations of viral hepatitisZ01DK054514 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI HELLER, THEO · 2007 to 2008
$838k
Co(II)-Radical Pair Dynamics in B12 Enzyme CatalysisR56DK054514 · NIDDK · EMORY UNIVERSITY · PI WARNCKE, KURT · 2008 to 2014
$151k
Intramural NIH HHS Z01 DK054514NIDDK NIH HHS R01 DK054514NIDDK NIH HHS R56 DK054514
6 · The paper itself

Abstract

Background: The microbiome of patients with hepatitis D virus (HDV) has yet to be characterized. This study aims to (1) characterize gut microbial composition in HDV, (2) determine its functional profile, (3) identify microbial species that contribute to changes in pathway expression, and (4) correlate the changes in the gut microbiome with clinical markers of disease severity. Methods: Cross-sectional analyses of 35 HDV-infected patients and 32 healthy controls (HCs) were performed. DNA and RNA were isolated from stool and sequenced by shotgun-sequencing. Microbial and functional profiles were compared between the HDV-cohort and HCs to identify disease-specific alterations to the gut microbiome. Clinical metadata were used to identify correlations with disease severity. Results: There were significant changes in the composition of the gut microbiome in HDV-infected patients as compared with HCs, spanning multiple bacterial phyla. Expression of 194 pathways was significantly increased in the HDV group. Pathways that were upregulated in the HDV cohort were related to amino acid and carbohydrate biosynthesis or involved important metabolic cofactors and carriers. Several microbial species, including Conclusion: There are significant differences in microbial composition between HDV and HCs, several of which are found to be altered in other liver diseases. Upregulated pathways suggest a broader dysregulation of energy metabolism, even in early disease. These findings provide insight into pathways that may lead to liver disease progression in HDV.

Indexed as

amino acidbiosynthesiscarbohydrateenergy metabolismgut–liver axismetagenomemetatranscriptomeportal vein

Identifiers

PMID42495136
PMCPMC13393096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.